Skip Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z

National Vaccine Program Office

Welcome Center | What's New | Publications | Contact Us
Search NVPO
  red flashing square  Vaccine Conference
  red flashing square  NVAC Report: Strengthening the Supply of Vaccines in the U.S.
  Registry Support for
  Immunization
  Programs
  Progress
  Report
  Immunization
  Registry
  Clearinghouse
  Influenza (flu)
  Season 2003-2004
  Pandemic Influenza
  NVAC Resolutions
  Meeting Materials
  Severe Acute
  Respiratory
  Syndrome
  Smallpox Planning
  and Response
  Unmet Needs Projects
  Immunization
  Concepts
  Immunization
  Laws
  If We Stop
  Vaccinating
  Vaccine Safety
  Q&A
  Some of the People
  Who Stand Behind
  Vaccinations
  10 Tips on Evaluating
  Immunization
  Information on the
  Internet


Proposal Number: N69
PI Name: Meysick, Karen
PI Email: meysick@cber.fda.gov
PI Title: Visiting Scientist
Project Title: Identification of potential vaccine antigen candidates associated with a novel Yersinia pestis chromosomal type III secretion system.
Project Start: 2003
Project End: 2005

Abstract: With the killed whole-cell plague vaccine no longer being manufactured, recombinant subunit vaccines are currently being sought. The goal of this project is to establish whether proteins associated with a recently described chromosomal type III secretion system (cTTSS), common to Yersinia pestis and Y. pseudotuberculosis, could provide new potential candidate antigens for use in a multivalent plague vaccine. The role of this new cTTSS, first described upon release of the Y. pestis genome sequence, has yet to be determined; however, it may be required for intracellular survival and bacterial replication within macrophages and epithelial cells. Based upon the high degree of sequence similarity this cTTSS shares with a TTSS contained within the Salmonella Pathogenicity Island 2 (SPI-2). In Salmonella, SPI-2 has been shown to be not only essential for bacterial survival and replication in macrophages, but is also required for dissemination and systemic infection. The specific aims of this project are to: 1) generate isogenic Yersinia strains defective in various components of the cTTSS and examine these mutants for their capacity to survive and replicate in macrophage cell lines as well as assess their lethality in mouse challenge studies, and 2) identify the environmental conditions under which this cTTSS is induced and the effector molecules that are secreted by this system. If the Yersinia cTTSS is found to be required for virulence, then components of this system and its associated effector molecules will be further characterized to determine whether these new target antigens are applicable in a subunit vaccine.

Institution: Food and Drug Administration

Date: July 2003


Return to Research Program Awards for Fiscal Year 2003


Welcome Center | What's New | Publications | Contact Us

CDC Home | Search | Health Topics A-Z

Last updated: July 16, 2003

URL: http://www.cdc.gov/od/nvpo/research/abn69.htm

Centers for Disease Control and Prevention
National Vaccine Program Office